Organization
Fresenius Kabi SwissBioSim
3 clinical trials
1 abstract
Clinical trial
A Randomized, Double-blind Trial to Evaluate the Efficacy, Safety and Immunogenicity of MSB11022 Compared With Humira® in Subjects With Moderate to Severe Chronic Plaque PsoriasisStatus: Completed, Estimated PCD: 2016-12-31
Clinical trial
A Randomized, Double-Blind, Multiple-Dose, Parallel-Group, Two-Arm Study to Evaluate the Efficacy, Safety and Immunogenicity of MSB11456 Compared to European Union-approved RoActemra® in Patients With Moderately to Severely Active Rheumatoid Arthritis (APTURA I Study)Status: Completed, Estimated PCD: 2021-08-31
Clinical trial
A Double-blind, Randomized, Multicenter, Multiple-dose, 2-arm, Parallel-group Study to Evaluate Efficacy, Pharmacodynamics, Safety, and Immunogenicity of FKS518 - Proposed Biosimilar to Denosumab With Prolia® in Postmenopausal Women With Osteoporosis (LUMIADE-3 Study)Status: Completed, Estimated PCD: 2023-08-07
Abstract
A randomised, double-blind trial comparing the efficacy, safety and immunogenicity of msb11022, a proposed biosimilar of adalimumab, versus adalimumab originator in patients with moderate-to-severe plaque psoriasisOrg: Charles University General University Hospital, Probity Medical Research Inc, University of Southampton, Fresenius Kabi SwissBioSim, Cytelligen, San Diego, CA,